BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 2521352)

  • 1. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans.
    Levitz SM; DiBenedetto DJ
    J Immunol; 1989 Jan; 142(2):659-65. PubMed ID: 2521352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans.
    Flesch IE; Schwamberger G; Kaufmann SH
    J Immunol; 1989 May; 142(9):3219-24. PubMed ID: 2496162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.
    Horwitz MA; Silverstein SC
    J Clin Invest; 1980 Jan; 65(1):82-94. PubMed ID: 6985617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Killing of Cryptococcus neoformans by rat alveolar macrophages.
    Bolaños B; Mitchell TG
    J Med Vet Mycol; 1989; 27(4):219-28. PubMed ID: 2677299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The defensive role of human pulmonary alveolar macrophages and polymorphonuclear leukocytes against a strongly or weakly virulent strains of Cryptococcus neoformans].
    Tabeta H; Kohno N; Kamei K; Honda A; Unno H; Nagao K; Yamaguchi T; Miyaji M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1174-9. PubMed ID: 1753544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages.
    Bolaños B; Mitchell TG
    J Med Vet Mycol; 1989; 27(4):203-17. PubMed ID: 2677298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential binding of acapsulate and encapsulated strains of Cryptococcus neoformans to human neutrophils.
    Richardson MD; White LJ; McKay IC; Shankland GS
    J Med Vet Mycol; 1993; 31(3):189-99. PubMed ID: 8360810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions.
    Zaragoza O; Taborda CP; Casadevall A
    Eur J Immunol; 2003 Jul; 33(7):1957-67. PubMed ID: 12884862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin.
    Levitz SM; Tabuni A
    J Clin Invest; 1991 Feb; 87(2):528-35. PubMed ID: 1991837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form.
    Cross CE; Bancroft GJ
    Infect Immun; 1995 Jul; 63(7):2604-11. PubMed ID: 7790075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.
    Levitz SM; DiBenedetto DJ
    Infect Immun; 1988 Oct; 56(10):2544-51. PubMed ID: 3138176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
    Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
    Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
    Kozel TR; Gotschlich EC
    J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
    Zaragoza O; Casadevall A
    Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum.
    Li RK; Mitchell TG
    J Med Vet Mycol; 1997; 35(5):327-34. PubMed ID: 9402525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans.
    Cross CE; Collins HL; Bancroft GJ
    Immunology; 1997 Jun; 91(2):289-96. PubMed ID: 9227330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates.
    Chaturvedi V; Wong B; Newman SL
    J Immunol; 1996 May; 156(10):3836-40. PubMed ID: 8621921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptococcus neoformans is resistant to surfactant protein A mediated host defense mechanisms.
    Giles SS; Zaas AK; Reidy MF; Perfect JR; Wright JR
    PLoS One; 2007 Dec; 2(12):e1370. PubMed ID: 18159253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity.
    Granger DL; Perfect JR; Durack DT
    J Immunol; 1986 Jan; 136(2):672-80. PubMed ID: 3510251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology of infection caused by Cryptococcus neoformans.
    Wormley FL; Perfect JR
    Methods Mol Med; 2005; 118():193-8. PubMed ID: 15888944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.